摘要
选择初次确诊的恶性淋巴瘤病例及正常人对照各30例。病例组于COP方案化疗前后各检测外周血IL—2活性1次,对照组只检测1次。结果表明:病例组治疗前IL—2活性显著低下,治疗后明显回升,但仍低于对照组(P<0.01)。治疗后IL—2活性及其升高程度,Ⅲ—Ⅳ期低于Ⅰ—Ⅱ期(P<0.02和P<0.05),部分缓解低于完全缓解(P<0.05),死亡及带瘤生存低于无瘤生存(P<0.01)。提出:肿瘤负荷可能是抑制IL—2活性的主要因素,IL—2活性检测有可能作为估计肿瘤患者预后的指标。
To study ralationship beteen interteukin 2 (JL-2) and carcinoma open up a new field in tumor immunity. In this study, the method of modified rapid detection of IL-2 activity with mouse thymocyte was applied. IL-2 activity of peripheral blood was detected in 30 malignant lymphoma patients with 30 normal person. Patients received assay before and after COP scheme chemotherapy. The results show that pretherapeutic IL-2 activity value is 6.51±1.18 u/ml, and posttherapeutic .increase to 13.78±2.69 u/ml, but control's, 26.40±14.79 u/ml. To compare each other, the differences are highly significant (P<0.01). The posttherapeu utic values and their increase degrees; of patients with stage Ⅲ-Ⅳ, partial response, and dead or tumor-bearing are lower than those with stage Ⅰ-Ⅱ (P<0.02, P<0.05), complete response (P<0.05), and free (P<0.01). There are no statistical significant (P>0.05) in the values of patients with different courses, pathological types, and positive or negative extranodal involvm-e.nts. In the discussion, we have suggested that 1. decrease of IL-2 activity is a probable feature of all patients, with carcinoma; 2. tumor load perhaps plays a major role to suppress IL-2 activity; 3. chemotherapy may increase IL-2 activity with decrement of the dose of tumor load; 4. it is difficult to get rid of suppression to IL-2 activity with exacerbation of malignant lymphoma patients; 5. IL-2 activity assay may be able to become a index to predict prognosis of patients with carcinoma.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1989年第2期104-108,共5页
Chinese Journal of Cancer
